These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

392 related items for PubMed ID: 23037643

  • 1. Agomelatine in depressive disorders: its novel mechanisms of action.
    Srinivasan V, Zakaria R, Othman Z, Lauterbach EC, Acuña-Castroviejo D.
    J Neuropsychiatry Clin Neurosci; 2012; 24(3):290-308. PubMed ID: 23037643
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Role of melatonin in mood disorders and the antidepressant effects of agomelatine.
    Srinivasan V, De Berardis D, Shillcutt SD, Brzezinski A.
    Expert Opin Investig Drugs; 2012 Oct; 21(10):1503-22. PubMed ID: 22876742
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Pathophysiology of depression: role of sleep and the melatonergic system.
    Srinivasan V, Pandi-Perumal SR, Trakht I, Spence DW, Hardeland R, Poeggeler B, Cardinali DP.
    Psychiatry Res; 2009 Feb 28; 165(3):201-14. PubMed ID: 19181389
    [Abstract] [Full Text] [Related]

  • 7. Therapeutic potential of agomelatine in epilepsy and epileptic complications.
    Vimala PV, Bhutada PS, Patel FR.
    Med Hypotheses; 2014 Jan 28; 82(1):105-10. PubMed ID: 24314750
    [Abstract] [Full Text] [Related]

  • 8. Beyond the monoaminergic hypothesis: agomelatine, a new antidepressant with an innovative mechanism of action.
    Kasper S, Hamon M.
    World J Biol Psychiatry; 2009 Jan 28; 10(2):117-26. PubMed ID: 19255935
    [Abstract] [Full Text] [Related]

  • 9. Emerging targets for the pharmacological treatment of depression: focus on melatonergic system.
    Catena-Dell'Osso M, Marazziti D, Rotella F, Bellantuono C.
    Curr Med Chem; 2012 Jan 28; 19(3):428-37. PubMed ID: 22335516
    [Abstract] [Full Text] [Related]

  • 10. Agomelatine: innovative pharmacological approach in depression.
    Popoli M.
    CNS Drugs; 2009 Jan 28; 23 Suppl 2():27-34. PubMed ID: 19708723
    [Abstract] [Full Text] [Related]

  • 11. Evidence of agomelatine's antidepressant efficacy: the key points.
    Eser D, Baghai TC, Möller HJ.
    Int Clin Psychopharmacol; 2007 Oct 28; 22 Suppl 2():S15-9. PubMed ID: 17917562
    [Abstract] [Full Text] [Related]

  • 12. Synergistic mechanisms involved in the antidepressant effects of agomelatine.
    Tardito D, Molteni R, Popoli M, Racagni G.
    Eur Neuropsychopharmacol; 2012 Oct 28; 22 Suppl 3():S482-6. PubMed ID: 22867907
    [Abstract] [Full Text] [Related]

  • 13. The emerging role of melatonin agonists in the treatment of major depression: focus on agomelatine.
    De Berardis D, Di Iorio G, Acciavatti T, Conti C, Serroni N, Olivieri L, Cavuto M, Martinotti G, Janiri L, Moschetta FS, Conti P, Di Giannantonio M.
    CNS Neurol Disord Drug Targets; 2011 Feb 28; 10(1):119-32. PubMed ID: 20874703
    [Abstract] [Full Text] [Related]

  • 14. Agomelatine, a novel intriguing antidepressant option enhancing neuroplasticity: a critical review.
    Pompili M, Serafini G, Innamorati M, Venturini P, Fusar-Poli P, Sher L, Amore M, Girardi P.
    World J Biol Psychiatry; 2013 Aug 28; 14(6):412-31. PubMed ID: 23530731
    [Abstract] [Full Text] [Related]

  • 15. Impact of the novel antidepressant agomelatine on disturbed sleep-wake cycles in depressed patients.
    Quera-Salva MA, Lemoine P, Guilleminault C.
    Hum Psychopharmacol; 2010 Apr 28; 25(3):222-9. PubMed ID: 20373473
    [Abstract] [Full Text] [Related]

  • 16. Bidirectional communication between sleep and circadian rhythms and its implications for depression: lessons from agomelatine.
    Pandi-Perumal SR, Moscovitch A, Srinivasan V, Spence DW, Cardinali DP, Brown GM.
    Prog Neurobiol; 2009 Aug 28; 88(4):264-71. PubMed ID: 19454302
    [Abstract] [Full Text] [Related]

  • 17. The melatonergic system in mood and anxiety disorders and the role of agomelatine: implications for clinical practice.
    De Berardis D, Marini S, Fornaro M, Srinivasan V, Iasevoli F, Tomasetti C, Valchera A, Perna G, Quera-Salva MA, Martinotti G, di Giannantonio M.
    Int J Mol Sci; 2013 Jun 13; 14(6):12458-83. PubMed ID: 23765220
    [Abstract] [Full Text] [Related]

  • 18. Agomelatine treatment corrects impaired sleep-wake cycle and sleep architecture and increases MT1 receptor as well as BDNF expression in the hippocampus during the subjective light phase of rats exposed to chronic constant light.
    Tchekalarova J, Kortenska L, Ivanova N, Atanasova M, Marinov P.
    Psychopharmacology (Berl); 2020 Feb 13; 237(2):503-518. PubMed ID: 31720718
    [Abstract] [Full Text] [Related]

  • 19. Therapeutic potential of melatonin agonists.
    Cardinali DP, Pandi-Perumal SR, Srinivasan V, Spence DW, Trakht I.
    Expert Rev Endocrinol Metab; 2008 Mar 13; 3(2):269-279. PubMed ID: 30764095
    [Abstract] [Full Text] [Related]

  • 20. Melatonin and melatonergic drugs on sleep: possible mechanisms of action.
    Srinivasan V, Pandi-Perumal SR, Trahkt I, Spence DW, Poeggeler B, Hardeland R, Cardinali DP.
    Int J Neurosci; 2009 Mar 13; 119(6):821-46. PubMed ID: 19326288
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 20.